Recently, we analyzed the hypermethylation status of the p16INK4a (p16) gene promoter in normal-appearing mucosa obtained from patients with colorectal cancer (CRC). p16 hypermethylation was associated with inferior survival of the patients. In the present study, germ line polymorphisms in the folate-and methyl-associated genes methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), and methionine synthase reductase (MTRR) were analyzed in the same patient cohort in order to find a possible link between these genetic variants and p16 hypermethylation.
INTRODUCTION
metabolism leading to genomic DNA hypomethylation (4) concomitant with genespecific promoter hypermethylation (5) , as is frequently observed in cancer. In addition, reduced MTHFR activity leads to increased plasma levels of homocysteine. Increased levels of homocysteine may promote inflammatory processes by generating reactive oxygen species (ROS) (6) . Hence, the metabolite has a crucial role in cellular oxidative stress. Homocysteine may also affect hypo-and hypermethylation of DNA (7) . Several case-control studies have shown that the MTHFR C677T polymorphism is protective against CRC (8-10), especially among individuals with a folate/methyl-sufficient diet (11,12). However, contradictive results have been found (13-16). Evaluation of the MTHFR C677T polymorphism as a predictive marker for CRC patients treated with 5-fluorouracil (5-FU)-based chemotherapy points to a possible link between the MTHFR 677 T allele and tumor response (10, (17) (18) (19) . Studies have also shown that the polymorphism might be associated with 5-FU-related cytotoxicity (19, 20) .
The MTR A2756G polymorphism leads to replacement of aspartic acid with glycine in the protein binding region of methionine synthase (MTR; EC 2.1.1.13) (21) . This substitution leads to a less effective enzyme that induces modest reduction of homocysteine (22, 23) where methyl(III)cobalamin, is generated (26). The MTRR A66G polymorphism leads to a substitution of isoleucine with methionine at codon 22 in the MTRR enzyme (27), resulting in a variant protein exhibiting a 4-fold lower activity compared to the wild-type protein in vivo (28). Thus, the MTRR 66 G allele should decrease the availability of SAM by reducing the level of active MTR. As a result, DNA hypomethylation may be induced. The MTR 2756 GG genotype has been associated with an increased risk of CRC (29), whereas a reduced risk of colorectal adenoma recurrence has been observed in patients heterozygous for the MTRR A66G polymorphism (30). The effects of the MTR A2756G and MTRR A66G variants seem to be influenced by folate intake (9,31).
The relationship between genetic polymorphisms, folate, and the p16 gene has been studied by a few research groups. Kraunz et al. (32) found that low dietary intake of folate was associated with p16 methylation in tumors of head and neck squamous cell carcinoma patients, and that this relationship was modified by the MTHFR genotype. 
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Blood Donors
The control group (n=300) consisted of Swedish Caucasian blood donors of either gender from the same geographic area as the cases. All samples were collected at random and informed consent was obtained from each of the donors.
Determination of p16 hypermethylation status
The hypermethylation status of p16 was determined using real-time PCR as described previously (3)
Genotyping of the MTHFR, MTR, and MTRR Genes
Genomic DNA was extracted from fresh-frozen blood using QIAamp DNA Mini Kit according to the manufacturers instructions (Qiagen, Hilden, Germany). Genotype analyses of the genes MTHFR (rs1801133, assay no. C_8714009_10), MTR (rs1805087, assay no. C_12005959_10), and MTRR (rs1801394, assay no. C_3068176_10) were run on an ABI PRISM® 7900HT sequence detection system (Applied Biosystems, Foster City, CA, USA) using real-time PCR and TaqMan chemistry. The SNP assays (Applied Biosystems, Foster City, CA, USA) and the TaqMan PCR master mix (Applied Biosystems, Foster City, CA, USA) were aliquoted into a 384-well plate using a liquid- 
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RESULTS
Distribution of Genotypes in CRC Patients and Healthy Controls
To investigate whether the MTHFR C677T, MTR A2756G, and MTRR A66G polymorphisms were predictive for CRC, we compared the genotype frequencies of patients with those of 300 healthy Caucasian blood donors ( Table 1 ). As shown in the table, the genotype distributions of the patient group were not significantly different from that of the control group. Furthermore, none of the clinical or pathological parameters (gender, age, tumor location, tumor differentiation grade, or tumor stage) were associated with genotypes (data not shown). The MTHFR C677T, MTR A2756G, and MTRR A66G genotype distributions were in Hardy-Weinberg equilibrium in both patients and controls. Table 2 shows the result of the MTHFR C677T, MTR A2756G, and MTRR A66G analyses when the CRC patients were dichotomized by p16 hypermethylation status in mucosa. As shown, the MTHFR 677 TT homozygous genotype was more common among patients with hypermethylated p16 compared to patients without hypermethylation, 10/62 (16.1%) and 8/113 (7.1%), respectively, but the difference did not reach significance. No differences were found when the MTR and MTRR genotype distributions were dichotomized according to p16 hypermethylation status.
Association of p16 Hypermethylation with the MTHFR, MTR, and MTRR Genotypes
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MTHFR, MTR, and MTRR Genotypes and Survival of Stage I-III Patients
Dichotomized by p16 Hypermethylation in Mucosa
The clinical follow-up time of the patients was extended in the present study compared to the previous one, and all patients had now been followed for at least five years. Because of this, the survival data was reanalyzed to examine whether p16 hypermethylation in mucosa was still a risk factor for cancer-specific and disease-free survival of patients 
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DISCUSSION
The major mechanism of p16 gene inactivation associated with development of CRC seems to be promoter region methylation (36) . Recently, Belshaw et al. (37) showed that multinomial logistic regression models based on the CpG island methylation profiles from normal mucosa could be used to distinguish cancer patients from non-cancer patients and that p16 was one of the most informative variables. As previously reported by us (3), the hypermethylation status of the p16 gene promoter in mucosa obtained 10 cm from the tumor site was associated with outcome of the CRC patients. In the present study, the same patient cohort was analyzed regarding the possible link between genetic germ line polymorphisms of the genes MTHFR, MTR, and MTRR and the hypermethylation status of p16.
MTHFR, MTR, and MTRR are important enzymes in the folate and methyl pathways and each enzyme has polymorphic variants that might be associated with risk of CRC.
However, the data showed that the genotype distributions of these genes did not differ significantly between patient and control groups indicating that none of the genetic variants had influenced the cancer susceptibility. There appeared to be no link between any of the polymorphic variants and the p16 methylation status because no significant differences according to genotype distributions in patients sub-grouped by p16 hypermethylation status could be found. Because the clinical follow-up time of the patients was extended in the present studycompared to the previous one, we reanalyzed the survival data. As before, p16 hypermethylation was found to be an independent Molecular Medicine www.molmed.org UNCORRECTED PROOF prognostic marker for cancer-specific survival. None of the genetic variants MTHFR C677T, MTR A2756G or MTRR A66G were related to cancer-specific or disease-free survival when the whole group of stage I-III patients was analyzed. However, patients with the MTRR 66 AA/AG genotype had a significantly worse cancer-specific survival if the p16 gene was hypermethylated in mucosa. In contrast, there was no difference in survival related to p16 hypermethylation among patients with the MTRR 66 GG genotype.
The reason for the particularly unfavorable outcome of patients having the combination of the MTRR 66 AA/AG genotype and p16 hypermethylation in mucosa might be linked to a state of chronic inflammation and oxidative stress. Chen et al. found that a number of inflammation markers were altered in mucosa of patients with CRC as compared to controls (38) . These alterations could be found in mucosa several cm from the tumor site.
It is known that a long-standing chronic inflammation in the colorectal epithelium will lead to oxidative stress (39), a condition which is considered to be one of the major sources of carcinogenesis. Growing evidence support a role of reactive oxygen species (ROS)-induced generation of oxidative stress in epigenetic changes like hypo-and hypermethylation (40) . Interestingly, inactivation of p16 by homozygous deletion or methylation at the promoter region seems to be a common molecular mechanism in During the state of chronic inflammation, DNA damage and mutations will be induced by increased production of ROS and electrophiles. Consequently, the need for folates utilized in DNA synthesis and repair will be increased. Since folates are very susceptible to oxidation, an increased oxidative degradation of folates may become relevant under oxidative stress conditions. Thus, oxidative stress could represent an endogenous reason for folate deficiency, even when the dietary intake is within the recommended range (47).
The relationship between promoter methylation of genes involved in colorectal carcinogenesis, including p16, and folate was recently investigated (48). The results showed that low folate/high alcohol intake was associated with increased gene promoter hypermethylation in CRC. In our previously published study (3), FPGS gene expression (used as a surrogate marker for folate) was shown to be lower in mucosa with, compared to without, p16 hypermethylation. The difference did not reach significance (p=0.079), however, possibly due to the limited number of samples that could be analyzed.
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Folates are needed in the elimination of homocysteine via both the transmethylation and the transsulfuration pathways (49). Under physiological conditions, the strongest risk factor for hyperhomocysteinemia seems to be low serum folate levels (7) . In cases of increased oxidative stress, however, the homocysteine level may not reflect folate deficiency but rather a deficiency in vitamin B 12 (cobalamin) (50). Markedly elevated concentrations of homocysteine have been found in colonic mucosa of inflammatory bowel disease (IBD) patients (51,52). In patients with Crohn's disease (CD) the MTRR A66G polymorphism was shown to be associated with oxidant stress and disease activity whereas vitamin B 12 and the MTHFR 677 TT genotype were the main determinants of hyperhomocysteinemia (53) . The MTRR 66 AA genotype was a significant independent predictor of CD risk and patients with this genotype had significantly higher levels of the oxidative stress marker superoxide dismutase. Thus, it is possible that CRC patients having the MTRR 66 AA variant are more pre-disposed to oxidative stress.
Although the relatively small number of cases included in the present study leads to a Some of the discrepancies that have been noted regarding the effects of genotypes are probably caused by differences among study populations relating to the average intake of dietary factors. Interactions between genotype and folate may only be detected in patients with high or low plasma folate levels (11,12,55) or in patients receiving folate supplements (30). Thus, the lack of analysis of micronutrients in the tissue samples is a limitation of the present study. However, large populations are required to examine genenutrient interactions using traditional epidemiological methods. 
